ALIGOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8101 USD | -4.24% |
|
+3.59% | +22.00% |
Chart calendar Aligos Therapeutics, Inc.
f7b06a7f420c888b.j55qMG0WbPaeTNYFiOd0KheoGcB8_o7hv5C_v_FaABk.xscCYkBTI5PnCuda8a08B0_jL4dLj-S47eTU8JAFXyvK2CcdPG88xucb7g~43ea66669d8d9430e52c1bf328f6dc93
Upcoming events on Aligos Therapeutics, Inc.
Past events on Aligos Therapeutics, Inc.
| 28/04/2024 07:30 | European Society of Clinical Microbiology and Infectious Diseases Meeting |
| 15/04/2024 | Piper Sandler Spring Biopharma Symposium |
| 28/03/2024 08:10 | Asian Pacific Association for the Study of the Liver Meeting - Poster No ALG-055009 |
| 28/03/2024 00:57 | Asian Pacific Association for the Study of the Liver Meeting - Oral No. ALG-000184 |
| 28/03/2024 00:48 | Asian Pacific Association for the Study of the Liver Meeting - Oral No. ALG-000184 |
| 28/03/2024 00:30 | Asian Pacific Association for the Study of the Liver Meeting - Oral No. ALG-000184 |
| 12/03/2024 20:05 | Q4 2023 Earnings Release |
| 10/03/2024 | Leerink Partners Global Biopharma Conference |
| 07/03/2024 21:00 | Investor Meeting - Key Opinion Leader |
| 30/11/2023 17:30 | Piper Sandler Healthcare Conference |
| 16/11/2023 18:30 | Investor Meeting |
| 12/11/2023 | American Association for the Study of Liver Diseases Conference - Poster No. #5028-C |
| 02/11/2023 20:05 | Q3 2023 Earnings Release |
| 03/08/2023 21:05 | Q2 2023 Earnings Release |
| 20/07/2023 16:00 | Annual General Meeting |
| 20/06/2023 | European Association for the Study of the Liver Congress - Hepatocellular Carcinoma |
| 20/06/2023 | European Association for the Study of the Liver Congress - Hepatitis B Virus Model System |
| 20/06/2023 | European Association for the Study of the Liver Congress - SI-RNA PD L1 Inhibitor |
| 20/06/2023 | European Association for the Study of the Liver Congress - Small Molecule PD-L1 Inhibitor ALG-093702 |
| 20/06/2023 | European Association for the Study of the Liver Congress - Pharmacodynamic Durability Of ALG-12575 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 4,36 4,00 9.06% | 13,9 12,5 10.88% | 9,34 14,4 -35.26% | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -97,8 -96,0 -1.87% | -128 -128 -0.16% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -97,8 -97,1 -0.71% | -128 -127 -0.98% | -97,6 -96,3 -1.31% | -88,1 -80,8 -9.11% | -108 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -108 -99,1 -9.37% | -128 -127 -1.12% | -95,9 -95,4 -0.62% | -86,9 -77,6 -11.96% | -108 |
|
Net income Million USD | Released Forecast Spread | -52,4 | -109 -99,1 -9.52% | -128 -127 -1.16% | -96,0 -95,1 -0.97% | -87,7 -77,8 -12.75% | -107 |
|
EPS USD | Released Forecast Spread | -2,78 | -10,9 -6,19 -75.61% | -3,22 -3,15 -2.25% | -2,25 -2,23 -0.9% | -1,36 -1,65 17.58% | -0,84 |
| Announcement Date | 26/08/20 | 23/03/21 | 10/03/22 | 09/03/23 | 12/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,37 0,00 - | 2,57 0,00 - | 3,69 0,00 - | 4,11 0,75 447.47% | 3,54 2,15 64.51% | 2,72 0,00 - | 6,89 0,00 - | 3,24 2,50 29.56% | 2,01 1,60 25.56% | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -37,9 -36,6 -3.65% | -35,6 -32,2 -10.42% | -20,4 -31,7 35.57% | -18,9 -25,7 26.29% | -22,7 -21,4 -6.07% | -23,9 -21,4 -11.99% | -19,1 -21,8 12.17% | -19,1 -21,2 10.03% | -26,0 -18,6 -39.46% | -24,7 | -26,3 | -27,5 | -29,1 | -30,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -37,8 -36,6 -3.29% | -35,6 -32,1 -10.67% | -19,9 -30,9 35.67% | -18,7 -25,5 26.92% | -21,8 -21,3 -2.6% | -22,9 -21,4 -7.3% | -18,0 -21,8 17.25% | -18,0 -21,2 15.03% | -27,9 -18,6 -49.79% | -24,7 | -26,3 | -27,5 | -29,1 | -30,3 |
|
Net income Million USD | Released Forecast Spread | -37,7 -36,4 -3.51% | -35,6 -30,8 -15.65% | -19,9 -28,3 29.68% | -18,6 -24,9 25.23% | -21,9 -21,0 -4.03% | -23,0 -20,9 -9.95% | -18,8 -21,3 11.77% | -18,0 -20,5 11.99% | -27,9 -18,0 -54.78% | -24,5 | -26,4 | -27,5 | -28,5 | -30,3 |
|
EPS USD | Released Forecast Spread | -0,89 -0,83 -7.39% | -0,84 -0,73 -15.46% | -0,47 -0,67 29.63% | -0,44 -0,58 24.25% | -0,51 -0,49 -4.08% | -0,53 -0,49 -9.28% | -0,43 -0,50 13.13% | -0,41 -0,48 13.68% | -0,22 -0,27 18.52% | -0,19 | -0,21 | -0,22 | -0,23 | -0,23 |
| Announcement Date | 10/03/22 | 04/05/22 | 04/08/22 | 02/11/22 | 09/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 12/03/24 | - | - | - | - | - |
More events
Past sector events for Aligos Therapeutics, Inc.
| 02/05/2024 21:10 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:05 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:05 | RELAY THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 21:01 | GALAPAGOS NV: Q1 2024 Earnings Release |
| 02/05/2024 13:00 | ALNYLAM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 12:05 | SHATTUCK LABS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | BLUEPRINT MEDICINES CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | KYMERA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | IQVIA HOLDINGS INC.: Q1 2024 Earnings Release |
| 02/05/2024 11:30 | MODERNA, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALGS Stock
- Calendar Aligos Therapeutics, Inc.
